Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 4 records in total 4
    records per page

    Critical Complications of COVID-19: A systematic Review and Meta-Analysis study

    Authors: Kimia Vakili; Mobina Fathi; Fatemeh Sayehmiri; Ashraf Mohamadkhani; Mohammadreza Hajiesmaeili; Mostafa Rezaei-Tavirani; Aiyoub Pezeshgi

    doi:10.1101/2020.06.14.20130955 Date: 2020-06-16 Source: medRxiv

    Background: Coronavirus disease 2019 (COVID-19) is a novel coronavirus infection MESHD that has spread worldwide in a short period and caused a pandemic. The goal of this meta-analysis is to evaluate the prevalence SERO of most common symptoms and complications of COVID-19. Methods: All related studies assessing the clinical complications of COVID-19 have been identified through web search databases (PubMed and Scopus). Relevant data were extracted from these studies and analyzed by stata (ver 14) random-effects model. The heterogeneity of studies were assessed by I2 index. The publication bias was examined by Funnel plots and Eggers test. Results: 30 studies were in our meta-analysis including 6 389 infected MESHD patients. The prevalence SERO of most common symptoms were: fever HP 84.30% (95% CI: 77.13-90.37; I2=97.74%), cough HP 63.01% (95% CI: 57.63-68.23; I2=93.73%), dyspnea HP dyspnea MESHD 37.16% (95% CI: 27.31-47.57%; I2=98.32%), fatigue HP fatigue MESHD 34.22% (95% CI: 26.29-42.62; I2=97.29%) and diarrhea HP diarrhea MESHD 11.47 %(95% CI: 6.96-16.87; I2=95.58%), respectively. The most prevalent complications were acute respiratory distress HP syndrome (ARDS) 33.15% (95% CI: 23.35-43.73; I2=98.56%), acute cardiac injury 13.77% (95% CI: 9.66-18.45; I2=91.36%), arrhythmia HP 16.64% (95% CI: 9.34-25.5; I2=92.29%), heart failure 11.50% (95% CI: 3.45-22.83; I2=89.48%), and acute kidney injury HP (AKI) 8.40 %(95% CI: 5.15-12.31; I2=95.22%, respectively. According to our analysis, mortality rate of COVID-19 patients were 12.29% (95% CI: 6.20-19.99; I2=98.29%). Conclusion: We assessed the prevalence SERO of the main clinical complications of COVID-19 and found that after respiratory complications, cardiac and renal complications are the most common clinical complications of COVID-19.

    Incidence and risk factors of kidney impairment MESHD on patients with COVID-19: a systematic review and meta-analysis

    Authors: Qixin Yang; Xiyao Yang

    doi:10.1101/2020.05.28.20116400 Date: 2020-06-03 Source: medRxiv

    Background: The novel coronavirus is pandemic around the world. Several researchers have given the evidence of impacts of COVID-19 on the respiratory, cardiovascular and gastrointestinal system MESHD. Studies still have debated on kidney injury MESHD of COVID-19 patients. The purpose of the meta-analysis was to evaluate the association of kidney impairment MESHD with the development of COVID-19. Methods: The PubMed, Embase and MedRxiv databases were searched until April 1, 2020. We extracted data from eligible studies to summarize the clinical manifestations and laboratory indexes of kidney injury MESHD on COVID-19 infection MESHD patients and further compared the prevalence SERO of acute kidney injury HP acute kidney injury MESHD ( AKI MESHD) and the mean differences of three biomarkers between in ICU/severe and non-ICU/non-severe cases. Heterogeneity was evaluated using the I2 method. Results: In the sum of 19 studies with 4375 patients were included in this analysis. The pooled prevalence SERO of AKI MESHD, increased serum SERO creatinine (Scr), increased blood urea nitrogen HP blood SERO urea nitrogen (BUN), increased D-dimer, proteinuria HP proteinuria MESHD and hematuria HP hematuria MESHD in patients with COVID-19 were 7.7%, 6.6%, 6.2%, 49.8%, 42% and 30.3% respectively. Moreover, the means of Scr, BUN and D-dimer were shown 6-folds, 1.8-folds and 0.68-folds, respectively, higher in ICU/severe cases than in corresponding non-ICU/non-severe patients. The prevalence SERO of AKI MESHD was about 17 folds higher in ICU/severe patients compared with the non-ICU/non-severe cases. Conclusions: Overall, we assessed the incidences of the clinic and laboratory features of kidney injury MESHD in COVID-19 patients. And kidney dysfunction MESHD may be a risk factor for COVID-19 patients developing into the severe condition. In reverse, COVID-19 can also cause damage to the kidney.

    Acute kidney injury HP kidney injury MESHD in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study

    Authors: Guanhua Xiao; Hongbin Hu; Feng Wu; Tong Sha; Qiaobing Huang; Haijun Li; Jiafa Han; Wenhong Song; Zhongqing Chen; Zhenhua Zeng

    doi:10.1101/2020.04.06.20055194 Date: 2020-04-08 Source: medRxiv

    Background: The kidney may be affected in coronavirus-2019 disease (COVID-19). This study assessed the predictors and outcomes of acute kidney injury HP acute kidney injury MESHD ( AKI MESHD) among individuals with COVID-19. Methods: This observational study, included data on all patients with clinically confirmed COVID-19 admitted to Hankou Hospital, Wuhan, China from January 5 to March 8, 2020. Data were extracted from clinical and laboratory records. Follow-up was censored on March 8, 2020. This is a single-center, retrospective, observational study. Patients clinically confirmed COVID-19 and admitted to Hankou Hospital, Wuhan, China from January 5 to March 8, 2020 were enrolled. We evaluated the association between changes in the incidence of AKI MESHD and COVID-19 disease and clinical outcomes by using logistic regression models. Results: A total of 287 patients, 55 with AKI MESHD and 232 without AKI MESHD, were included in the analysis. Compared to patients without AKI MESHD, AKI MESHD patients were older, predominantly male TRANS, and were more likely to present with hypoxia MESHD and have pre-existing hypertension HP hypertension MESHD and cerebrovascular disease MESHD. Moreover, AKI MESHD patients had higher levels of white blood SERO cells, D-dimer, aspartate aminotransferase, total bilirubin, creatine kinase, lactate dehydrogenase, procalcitonin, C-reactive protein, a higher prevalence SERO of hyperkalemia HP hyperkalemia MESHD, lower lymphocyte counts, and higher chest computed tomographic scores. The incidence of stage 1 AKI MESHD was 14.3%, and the incidence of stage 2 or 3 AKI MESHD was 4.9%. Patients with AKI MESHD had substantially higher mortality. Conclusions: AKI MESHD is an important complication of COVID-19. Older age TRANS, male TRANS, multiple pre-existing comorbidities, lymphopenia HP lymphopenia MESHD, increased infection indicators, elevated D-dimer, and impaired heart and liver functions MESHD were the risk factors of AKI MESHD. AKI MESHD patients who progressed to stages 2 or 3 AKI MESHD had a higher mortality rate. Prevention of AKI MESHD and monitoring of kidney function is very important for COVID 19 patients.

    Kidney impairment MESHD is associated with in-hospital death of COVID-19 patients

    Authors: Yichun Cheng; Ran Luo; Kun Wang; Meng Zhang; Zhixiang Wang; Lei Dong; Junhua Li; Ying Yao; Shuwang Ge; Gang Xu

    doi:10.1101/2020.02.18.20023242 Date: 2020-02-20 Source: medRxiv

    Background: Information on kidney impairment MESHD in patients with coronavirus disease MESHD 2019 (COVID-19) is limited. This study aims to assess the prevalence SERO and impact of abnormal urine analysis and kidney dysfunction MESHD in hospitalized COVID-19 patients in Wuhan. Method: We conducted a consecutive cohort study of COVID-19 patients admitted in a tertiary teaching hospital with 3 branches following a major outbreak in Wuhan in 2020. Hematuria HP Hematuria MESHD, proteinuria HP proteinuria MESHD, serum SERO creatinine concentration and other clinical parameters were extracted from the electronic hospitalization databases and laboratory databases. Incidence rate for acute kidney injury HP kidney injury MESHD ( AKI MESHD) was examined during the study period. Association between kidney impairment MESHD and in-hospital death was analyzed. Results: We included 710 consecutive COVID19 patients, 89 (12.3%) of whom died in hospital. The median age TRANS of the patients was 63 years (inter quartile range, 51-71), including 374 men and 336 women. On admission, 44% of patients have proteinuria HP proteinuria MESHD hematuria HP and 26.9% have hematuria HP hematuria MESHD, and the prevalence SERO of elevated serum creatinine HP serum SERO creatinine and blood SERO urea nitrogen were 15.5% and 14.1% respectively. During the study period, AKI MESHD occurred in 3.2% patients. Kaplan-Meier analysis demonstrated that patients with kidney impairment MESHD have higher risk for in-hospital death. Cox proportional hazard regression confirmed that elevated serum creatinine HP serum SERO creatinine, elevated urea nitrogen, AKI, proteinuria HP proteinuria MESHD and hematuria HP hematuria MESHD was an independent risk factor for in-hospital death after adjusting for age TRANS, sex, disease severity, leukocyte count and lymphocyte count. Conclusion: The prevalence SERO of kidney impairment MESHD ( hematuria HP hematuria MESHD, proteinuria HP proteinuria MESHD and kidney dysfunction MESHD) in hospitalized COVID-19 patients was high. After adjustment for confounders, kidney impairment MESHD indicators were associated with higher risk of in-hospital death. Clinicians should increase their awareness of kidney impairment MESHD in hospitalized COVID-19 patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.